Alkylating Anticancer Agents and Their Relations to MicroRNAs

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582140

Authors

Bernhard Biersack

Affiliations

Soon will be listed here.

Abstract

Alkylating agents represent an important class of anticancer drugs. The occurrence and emergence of tumor resistance to the treatment with alkylating agents denotes a severe problem in the clinics. A detailed understanding of the mechanisms of activity of alkylating drugs is essential in order to overcome drug resistance. In particular, the role of non-coding microRNAs concerning alkylating drug activity and resistance in various cancers is highlighted in this review. Both synthetic and natural alkylating agents, which are approved for cancer therapy, are discussed concerning their interplay with microRNAs.

Citing Articles

Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.

Jarmila P, Veronika M, Peter M Int J Pharm X. 2024; 8:100281.

PMID: 39297017 PMC: 11408389. DOI: 10.1016/j.ijpx.2024.100281.

Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents.

Rushing B Int J Mol Sci. 2023; 24(17).

PMID: 37686047 PMC: 10487847. DOI: 10.3390/ijms241713242.

Epigenetic basis of cancer drug resistance.

Aziz M, Ahmad A Cancer Drug Resist. 2022; 3(1):113-116.

PMID: 35582041 PMC: 9094056. DOI: 10.20517/cdr.2020.06.

References

Wu H, Liu Q, Cai T, Chen Y, Liao F, Wang Z . MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated gene-1. Diagn Pathol. 2014; 9:173. PMC: 4195982. DOI: 10.1186/s13000-014-0173-0. View

Al-Khanbashi M, Caramuta S, Alajmi A, Al-Haddabi I, Al-Riyami M, Lui W . Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. PLoS One. 2016; 11(4):e0152032. PMC: 4827834. DOI: 10.1371/journal.pone.0152032. View

Feng Y, Tsao C . Emerging role of microRNA-21 in cancer. Biomed Rep. 2016; 5(4):395-402. PMC: 5038362. DOI: 10.3892/br.2016.747. View

Emadi A, Jones R, Brodsky R . Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009; 6(11):638-47. DOI: 10.1038/nrclinonc.2009.146. View

Wang L, Shi Z, Jiang C, Liu X, Chen Q, Qian X . MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget. 2014; 5(14):5416-27. PMC: 4170647. DOI: 10.18632/oncotarget.2116. View

Shi L, Zhang S, Feng K, Wu F, Wan Y, Wang Z . MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2011; 40(1):119-29. DOI: 10.3892/ijo.2011.1179. View

Comincini S, Allavena G, Palumbo S, Morini M, Durando F, Angeletti F . microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biol Ther. 2013; 14(7):574-86. PMC: 3742487. DOI: 10.4161/cbt.24597. View

Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y . Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 2011; 27(3):854-60. DOI: 10.3892/or.2011.1535. View

Hu Y, Qiu Y, Yague E, Ji W, Liu J, Zhang J . miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis. 2016; 7(6):e2291. PMC: 5108343. DOI: 10.1038/cddis.2016.194. View

10.

WAKAKI S, MARUMO H, Tomioka K, Shimizu G, Kato E, Kamada H . Isolation of new fractions of antitumor mitomycins. Antibiot Chemother (Northfield). 2014; 8(5):228-40. View

11.

Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L . c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. Brain. 2015; 138(Pt 12):3654-72. DOI: 10.1093/brain/awv287. View

12.

Weeraratne S, Amani V, Neiss A, Teider N, Scott D, Pomeroy S . miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2010; 13(2):165-75. PMC: 3064629. DOI: 10.1093/neuonc/noq179. View

13.

Jones K, Nourse J, Keane C, Bhatnagar A, Gandhi M . Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res. 2013; 20(1):253-64. DOI: 10.1158/1078-0432.CCR-13-1024. View

14.

Chen P, Cheng C, Shih C, Ho K, Lin C, Lee C . The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death. PLoS One. 2016; 11(11):e0167096. PMC: 5125683. DOI: 10.1371/journal.pone.0167096. View

15.

Chen H, Li X, Li W, Zheng H . miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. J Transl Med. 2015; 13:69. PMC: 4345002. DOI: 10.1186/s12967-015-0435-y. View

16.

Berglund M, Hedstrom G, Amini R, Enblad G, Thunberg U . High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. Oncol Rep. 2012; 29(2):720-4. DOI: 10.3892/or.2012.2173. View

17.

Garcia-Vazquez R, Ruiz-Garcia E, Meneses Garcia A, Astudillo-de la Vega H, Lara-Medina F, Alvarado-Miranda A . A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer. Tumour Biol. 2017; 39(6):1010428317702899. DOI: 10.1177/1010428317702899. View

18.

Wei C, Pan Y, Huang H, Li Y . Estramustine phosphate induces prostate cancer cell line PC3 apoptosis by down-regulating miR-31 levels. Eur Rev Med Pharmacol Sci. 2018; 22(1):40-45. DOI: 10.26355/eurrev_201801_14098. View

19.

Tomasz M . Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995; 2(9):575-9. DOI: 10.1016/1074-5521(95)90120-5. View

20.

Peraldo Neia C, Cavalloni G, Chiorino G, Ostano P, Aglietta M, Leone F . Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget. 2016; 7(52):86766-86780. PMC: 5349952. DOI: 10.18632/oncotarget.13575. View